BD Opens New €4 Million R&D Centre in Dublin, Will Invest Additional €30 Million in Enniscorthy Manufacturing Plant
New Investments by BD to Add More Than 85 New Jobs in Ireland

DUBLIN (2 June 2023) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today held a grand opening ceremony for a new €4 million research and development facility in Blackrock, Dublin and announced an additional €30 million investment to expand its manufacturing facility in Enniscorthy, Wexford. The two investments will create more than 85 new jobs in Ireland.

The new 10,600 sq. ft. purpose-built R&D facility in Blackrock will house 35 high-tech workers and complements BD’s R&D facility in Limerick, which employs more than 300 people. The Blackrock R&D facility will focus on the commercialization of BD’s first on-body injector device, known as the BD Evolve™ On-Body Injector. With the majority of new pharmaceuticals in the pipeline being injectable drugs, BD has innovated new injection devices to meet this growing need. The facility will also serve as the regional base of operations for BD’s Sales, Technical Service and Corporate Functional Support Teams.

At the grand opening ceremony, BD officials also announced a new €30 million investment to expand its existing manufacturing facility in Enniscorthy, which will create approximately 85 new jobs. The new 40,000 sq. ft. expansion will house operations to manufacture a new medical technology from BD’s Peripheral Intervention business unit.

Joining BD executives at the grand opening ceremony were Minister of State for the Department of Enterprise, Trade and Employment Neale Richmond and IDA Executive Director Mary Buckley. 

Minister of State for the Department of Enterprise, Trade and Employment Neale Richmond TD said: “I am delighted with BD's announcement of a €4 million research and development facility in Blackrock, Dublin and additional €30 million expansion investment in Enniscorthy, Wexford. The projects will create more than 85 new jobs in Ireland with opportunities for our talented workforce to be part of exciting new medical advancements at BD. It is of course always great to see regional job creation, and the Government are always hugely supportive of such announcements.

Thanks to all the executives at BD for your continued investment and trust in Ireland.  I wish all the team the very best with both projects.”

IDA Ireland CEO Michael Lohan said: “BD has had a presence in Ireland for over 50 years, and these significant investments, adding a further 85 jobs and new facilities to its already substantial Irish operations and jobs, underscores the strategic importance of Ireland in BD’s global operations. It is proof of the company’s future commitment to the country and testament to Ireland and indeed our region’s continued attractiveness as a location for investment. I wish to assure BD of IDA Ireland’s continued support.’’

President of BD for Europe, Middle East and Africa Roland Goette said: “BD first established operations in Ireland in 1964, and since then has grown to four locations that employ more than 1,100 people across the country. Ireland has proven to be a smart place to invest in both R&D, as well as manufacturing operations, and our new R&D center in Blackrock and €30 million investment in Enniscorthy are proof of BD’s long-term commitment to Ireland. We look forward to continuing our long tradition of high-tech medical device innovation and manufacturing here.”

About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 77,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit or connect with us on LinkedIn at and Twitter @BDandCo.



Troy Kirkpatrick
VP, Public Relations


Francesca DeMartino
SVP, Head of Investor Relations